(Total Views: 472)
Posted On: 10/16/2020 12:11:11 AM
Post# of 145880
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: Borel Fields #61317
It could be OncoImmune was so close to full enrollment they decided to hold off for full trial results.
The effect of OncoImmune's drug is NF-kB inhibition and they had great results. Leronlimab also inhibits NF-kB and does more.
The effect of OncoImmune's drug is NF-kB inhibition and they had great results. Leronlimab also inhibits NF-kB and does more.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)